Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant DPX-Survivac with Letrozole +/- Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
NCT04895761Phase 1Active, not recruiting
- Start
- Sep 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of maveropepimut-S in breast cancer (3 arms). Primary endpoint: Number of participants without safety events (TASAEs, persistent grade III/IV TAAEs, or toxicity-related delays in curative-intent surgery). Started Sep 2021; status: active, not recruiting.
02
Drugs
maveropepimut-S
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04895761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895761.